Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Hexaxim vs Pentaxim + Engerix B in Healthy Infants
NCT00315055Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2006
- Primary completion
- Jul 2007
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hexaxim in hepatitis B (HBV), diphtheria, Tetanus and 3 more (2 arms), sponsored by Sanofi. Primary endpoint: Percentage of Participants With Anti HBs Seroprotection at Day 90. Started Jul 2006; status: completed.
02
Drugs
hexaxim
03
Conditions
hepatitis B (HBV)diphtheriaTetanuspertussispoliomyelitis
Beyond the preview
Go deeper on NCT00315055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00315055.